專業抑鈣素檢驗的全球市場 - 市場規模(各市場區隔)，佔有率，法規，償付，預測(～2033年)

本報告提供全球專業抑鈣素檢驗市場相關調查分析，提供各市場區隔的市場規模，市場趨勢，競爭情形，COVID-19影響等資訊。

市場模式的主要的內容如下列。

目前上市的專業抑鈣素檢驗和不斷變化的競爭格局

• 主要的產業趨勢考察
• 專業抑鈣素檢驗市場區隔的年度收益與市場預測(2015年～2033年)
• 單位，平均銷售價格，市場金額相關市場層級的資料

世界，地區，國家層級的市場具體考察

• 各地區分類的定性市場具體資訊各國考察與全球趨勢
• 專業抑鈣素檢驗市場SWOT分析
• 專業抑鈣素檢驗市場競爭動態的考察和趨勢

透過取得真正的大局（包括醫療保健系統的概述）來促進對市場的了解。此外，市場准入部分可讓您透過有關報銷政策和監管環境的資訊更深入地了解市場動態。

• 各國醫療制度概要
• 各國償付政策
• 各國醫療技術相關法規形勢

對象企業

• Abbott Laboratories
• Thermo Fisher Scientific Inc
• Danaher Corp
• F. Hoffmann-La Roche Ltd
• DiaSorin SpA
• bioMerieux SA,Bio-Rad laboratories Inc
• Siemens AG
• Quidelortho Corp and Diazyme Laboratories Inc
• 其他

Abstract

Procalcitonin Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

Sepsis is a life-threatening condition characterized by organ dysfunction caused by a patient's dysregulated response to infection. Sepsis is related to but distinct from septicemia, which is the spread of bacterial infection through the bloodstream; sepsis is the dysregulated host response to that infection. Advanced sepsis is associated with a high mortality rate (20-30%) with contributing factors including late diagnosis, inappropriate clinical management, and suboptimal quality of care. The age distribution of those with sepsis is largely biphasic, affecting predominantly newborns (and their mothers) and the elderly; patients of an advanced age with sepsis tend to have a broad array of comorbidities. Sepsis can progress rapidly to a condition known as septic shock, where profound circulatory, cellular, and metabolic abnormalities present with a larger risk of mortality.

Procalcitonin testing provides a means for distinguishing bacterial from viral infection and monitoring the efficacy of antibiotic treatment. However, such tests are not used exclusively for sepsis patients. Procalcitonin may be used for patients with Lower Respiratory Tract Infections (LRTI), bacterial Pneumonia, or for monitoring potential infection of patients requiring mechanical ventilation. Respiratory infections including various pneumonia are the most common cause of sepsis, and ventilated patients may also be septic in addition to other comorbidities. Due to the non-mutually exclusive nature of these conditions, sepsis has been chosen as the primary disease state and indication for this market model. All other indications requiring procalcitonin testing are intended to be covered under "Other Indications" on each country tab within this model.

Procalcitonin Tests Model includes Procalcitonin Enzyme Immunoassay Tests and Procalcitonin Other Tests

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Procalcitonin Test and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total Procalcitonin Tests market revenue by segment and market outlooks from

2015- 2033.

• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Procalcitonin Tests market.
• Competitive dynamics insights and trends provided for Procalcitonin Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific MedTech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corp, F. Hoffmann-La Roche Ltd, DiaSorin SpA, bioMerieux SA,Bio-Rad laboratories Inc, Siemens AG, Quidelortho Corp and Diazyme Laboratories Inc and others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Procalcitonin Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to:

• Understand the impact of COVID-19 on Procalcitonin Tests market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Procalcitonin Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Procalcitonin Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific Procalcitonin Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.